Multiple Sclerosis Patients' Benefit-Risk Preferences: Serious Adverse Event Risk versus Treatment Efficacy

Theodore Phillips; David Miller; Gordon Francis; Jeff White; Steve Hass; Semra Ozdemir; George Van Houtven; F Johnson

Multiple Sclerosis Patients' Benefit-Risk Preferences: Serious Adverse Event Risk versus Treatment Efficacy

Johnson, F., Van Houtven, G., Ozdemir, S., Hass, S., White, J., Francis, G., Miller, D., & Phillips, T. (2009). Multiple Sclerosis Patients' Benefit-Risk Preferences: Serious Adverse Event Risk versus Treatment Efficacy. Journal of Neurology, 256, 554 - 562.

Copy citation

Recent Publications

Article

The evolution of minimally invasive tissue sampling in postmortem examination

Article

Accountability for SRHR in the context of the COVID-19 pandemic

Article

Validation of simple dichotomous self-report on prenatal alcohol and other drug use in women attending midwife obstetric units in the Cape Metropole, South Africa

Multiple Sclerosis Patients' Benefit-Risk Preferences: Serious Adverse Event Risk versus Treatment Efficacy

Publications Info

Meet the Experts

George L. Van Houtven

Recent Publications

Article

The evolution of minimally invasive tissue sampling in postmortem examination

Article

Accountability for SRHR in the context of the COVID-19 pandemic

Article

Validation of simple dichotomous self-report on prenatal alcohol and other drug use in women attending midwife obstetric units in the Cape Metropole, South Africa

Article

Nicotinic acetylcholine receptor accessory subunits determine the activity profile of epibatidine derivatives